EGFR and adenocarcinoma: Although demographic and clinical factors such as East-Asian race, female gender, nonsmoking status, and adenocarcinoma were shown to be predictive of the efficacy of gefitinib, two pivotal studies showed that the presence of somatic mutations in the kinase domain of epidermal growth factor receptor (EGFR) strongly correlates with increased responsiveness to EGFR-TKIs in patients with nonsmall cell lung cancer [2, 3].